LAKEWOOD, Colo., Feb.
24, 2018 /PRNewswire/ -- Terumo BCT announced today that
it will be the exclusive distributor for Stafa Cellular Therapy
(StafaCT), a U.S.-based software developer. StafaCT software
supports healthcare facilities and cell labs as they manage each
phase of the cellular therapy process including patient referral,
cell collection and processing, transplant and
follow-up. Terumo BCT is a global leader in blood component,
therapeutic apheresis and cellular technologies.
Stem cell and immune effector cell transplants are used to treat
various blood cancers, immune system disorders and genetic
diseases. Given the significance of these treatments to patients,
StafaCT and Sarah Cannon Blood Cancer Network co-developed software
to manage each phase of the transplant process.
"Ensuring patients have access to the highest level of care
throughout the transplantation process is central to our mission,"
said Fred LeMaistre, M.D., Senior
Vice President and Physician-in-Chief of Blood Cancers,
Sarah Cannon. "By implementing
technologies that support improved patient outcomes and integrated
communication for the entire care team, we are setting a new
standard in patient care."
Terumo BCT will expand access to StafaCT software to healthcare
organizations. The software meets the needs of therapeutic
apheresis and cellular therapy procedures, including hematopoietic
cellular transplantation and immune effector cellular therapy.
Offering StafaCT software advances Terumo BCT's ongoing support
of the transplant and apheresis communities. For more than 30
years, Terumo BCT has been an innovator in therapeutic apheresis.
The Specta Optia® Apheresis System and the COBE
Spectra® Apheresis System are used predominantly
throughout the world. Now with StafaCT, Terumo BCT can also
streamline workflows and the collection and management of data
throughout the continuum of care.
"Not only does the software from StafaCT ultimately benefit
patients, it also helps to ensure the health of the organizations
that deliver that care," says Roy
Jones, M.D., Ph.D., former Chair of the Informatics
Committee for the American Society for Blood and Marrow
Transplantation.
About Terumo BCT
Terumo BCT, a global leader in blood
component, therapeutic apheresis and cellular technologies, is the
only company with the unique combination of apheresis collections,
manual and automated whole blood processing, and pathogen reduction
technologies. We believe in the potential of blood to do even more
for patients than it does today. This belief inspires our
innovation and strengthens our collaboration with customers.
About Stafa Cellular Therapy
Stafa Cellular Therapy (StafaCT) is a software company that
specializes in cellular therapy applications, including but not
limited to blood and marrow transplants. Its suite of products
covers data management, operational workflows, and compliance
monitoring for the entire cellular therapy process from the initial
referral to infusion and follow up. Formerly the cellular therapy
product team at Velos, StafaCT was spun out into its own company in
2015.
About The Sarah Cannon Blood Cancer
Network
Sarah Cannon brings
together physician-led blood cancer programs across the United States and United Kingdom to offer patients convenient
access to care including hematopoietic cell transplantation (HCT)
and clinical trials. For more information about the Network and
Sarah Cannon's full suite of
oncology services, visit sarahcannon.com.
Media Contact
Corporate Communications
Phone: +1.303.542.5396
press@terumobct.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/new-collaboration-with-stafact-will-optimize-patient-pathways-for-cellular-treatments-300603735.html
SOURCE Terumo BCT